Ranbaxy eyes U.S. drug launches with sales exclusivity

Ranbaxy Laboratories, India's No.1 drugmaker by sales, plans to file three to four generic drug applications every year that can earn it a six-month marketing exclusivity in the United States, the company's chief executive said on Thursday.

_0">

The first company that seeks approval from the U.S. Food and Drug Administration for a generic version of a patented medicine gets exclusive rights to sell it for 180 days after patent expiry.

 

"We have a very ambitious growth plan for our U.S. business," Arun Sawhney, told Reuters in an interview, a month after the company pleaded guilty in a U.S. Justice Department probe related to drug safety.

"We are targeting three to four first-to-file filings every year... We will be strengthening our dermatology business in the U.S. with a good slew of products in the future."

Ranbaxy is controlled by Japan's Daiichi Sankyo Co.

(Reporting by Kaustubh Kulkarni; Editing by Sunil Nair)

Popular posts from this blog

'I was his Christian Grey fantasy.' Ex-girlfriend Paige Lorenze says Armie Hammer carved an A into her groin area as she warns 'narcissistic' actor could 'seriously injure another woman' with his BDSM obsession

Model Stella Tennant dies 'suddenly' aged 50 as her family pay tribute to 'wonderful woman and an inspiration to us all'

Teenage boy, 15, charged after allegedly having sex with two 12-year-old girls and recording the encounter on his phone - but he's still allowed to go to school with them while on bail